Structure Therapeutics (NASDAQ:GPCR) Now Covered by William Blair

Analysts at William Blair initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR - Get Free Report) in a report released on Friday, MarketBeat Ratings reports. The firm set an "outperform" rating on the stock.

Several other research analysts have also commented on GPCR. JMP Securities reaffirmed a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $81.29.

Structure Therapeutics Trading Up 0.7 %

NASDAQ:GPCR traded up $0.15 during midday trading on Friday, hitting $22.49. 969,016 shares of the company were exchanged, compared to its average volume of 830,670. Structure Therapeutics has a fifty-two week low of $19.61 and a fifty-two week high of $62.74. The company has a market capitalization of $1.29 billion, a PE ratio of -30.39 and a beta of -2.75. The company has a fifty day simple moving average of $26.45 and a 200 day simple moving average of $33.47.

Remove Ads

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics in the 4th quarter valued at approximately $34,000. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth approximately $40,000. Finally, Assetmark Inc. raised its stake in shares of Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.